Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21225


The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.

Study summary:

This is a Phase 1 study to evaluate the safety, tolerability and PK of MGD010, a CD32B x CD79B DART bi-specific antibody-based molecule. This study will be conducted as a double-blind, randomized, placebo controlled, single ascending dose study among healthy subjects.


Inclusion Criteria: - Between 18 and 50 years of age - Body mass index (BMI) of 18 to 30 kg/m2, inclusive Exclusion Criteria: - Women of child-bearing potential; - Women who are pregnant or breast-feeding - Any significant acute or chronic medical illness - Any major surgery within 4 weeks of study drug administration - Active or latent tuberculosis (TB) - Active or latent Hepatitis B, Hepatitis C or HIV infection - History of allergy to monoclonal antibodies, any significant drug allergy (such as anaphylaxis), or hypersensitivity to any components of the test or reference investigational product formulation. - Evidence of organ dysfunction or any clinically significant deviation from normal - Vaccination with any live vaccine, or use of any prescription drugs, within 4 weeks of study drug administration - Known history of infection or exposure to Hepatitis A virus



Primary Contact:

Study Director
Sadhna Shankar, MD

Backup Contact:


Location Contact:

Baltimore, Maryland 21225
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 18, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.